Skip to main content


1. Leclercq IA et al: Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences.
J Hepatol 2007, 47:142-156.
2. Wieckowska A et al: Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and
future. Hepatology 2007, 46:582-589.
3. Chan H et al: How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol
Hepatol 2007, 22:801-808.
4. Balas B et al: Pioglitazone treatment increases whole body fat but not total body water in patients with
non-alcoholic steatohepatitis. J Hepatol 2007, 47:565-570.
5. Dufour JF: NASH and thiazolidinedions: not to be taken lightly. J Hepatol 2007, 47: 451-453.
6. Nissen SE et al: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular
causes. N Eng J Med. 2007, 356:
7. Lutchman G et al: The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis.
Hepatology 2007, 46:424-429.
8. Caldwell SH, Arga CK (Szerkesztõségi közl): Divergent effects of peroxisome proliferator-activated
receptor-? ligands in human and mouse nonalcoholic steatohepatitis. Hepatology 2007, 46:285-287.
9. Neuschwander-Tetri BA (szerkesztõségi közl): Food energy efficiency, cannabinoids and a slow death
of the weight loss dogma.Hepatology 2007, 46:12-15.
10. Oertelt S et al: A sensitive bead assay for antimitochodrial antibodies: chipping away at AMA-negative
primary biliary cirrhosis. Hepatology 2007, 45: 659-665.
11. Montano-Loza AJ et al: Features associated with treatment failure in type 1 autoimmune hepatitis and
predictive value of the model of end-stage liver disease. Hepatology 2007, 46: 1138-1145.
12. Umemura T et al: Immunoglobulin G4-hepatopathy: association of immunoglobulin G4-bearing plasma
A máj 319
cells in liver with autoimmune pancreatitis. Hepatology 2007, 46:463-471.
13. Schoepfer AM et al: Herbal does not mean innocuous: ten cases of severe hepatotoxicity associated with
dietary supplements from Herbalife® products. J Hepatol 2007, 47:521-526.
14. Elinav E et al: Association between consumption of Herbalife® nutritional supplements and acute
hepatotoxicity. J Hepatol 2007, 47:514-520.
15. Stickel F. (szerkesztõségi közl): Slimming at all costs: Herbalife®-induced liver injury. J Hepatol
2007, 47:444-446.
16. Bosetti et al: Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007, 46:827-839.
17. Garcia-Tsao G et al (AASLD practice guidelines): Prevention and management of gastroesophageal
varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922-938.
18. Thalheimer U et al: How to prevent varices from bleeding: shades of grey – the case for nonselective
ß blockers. Gastroenterology 2007, 133:2029-2036.
19. Imperiale TF et al: Cost-effectiveness analysis of variceal ligation vs. Beta-blockers for primary prevention
of variceal bleeding. Hepatology 2007, 45:870-878.
20. Arroyo V et al: Advances in the pathogenesis and the treatment of type-1 and type-2 hepatorenal syndrome.
J Hepatol 2007, 46:935-946.
21. Alessandria C et al: Noradrenalin vs terlipressin in patients with hepatorenal syndrome: aprospective,
randomized, unblinded, pilot study. J Hepatol 2007, 47: 499-505.
22. Krag A et al: Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal
syndrome. Hepatology 2007, 46: 1863-1871.
23. Ginés P et al (szerkesztõségi közl): Therapy with vasoconstrictor drugs in cirrhosis: the time has
arrived. Hepatology 2007, 46:1685-1687.
24. Fasolato S et al: Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical
features. Hepatology 2007, 45: 223-229.
25. Thabut D et al: Model for end-stage liver disease score and systemic inflammatory response are major
prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 2007, 46:
26. Fernández J et al: Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome
and improves survival in cirrhosis. Gastroenterology 2007, 133: 818-824
27. Runyon BA (szerkesztõségi közl): A pill a day can improve survival in patients with advanced cirrhosis.
Gastroenterology 2007, 133:1029-1031.
28. Salerno F et al: Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of
individual patient data. Gastroenterology 2007, 133:825-834.
29. Ginés P: Vaptans: a promising therapy in the management of advanced cirrhosis. J Hepatol 2007,
30. Tripodi A et al: The international normalized ratio calibrated for cirrhosis (INR liver) normalizes prothrombin
time results for model for end-stage liver disease calculation. Hepatology 2007, 46:520-527.
31. Bellest L et al: A modified international normalized ratio as an effective way of prothrombin time
standardization in hepatology. Hepatology 2007, 46:528-534.
32. Marlar R (szerkesztõségi közl.): Determining the model for end-stage liver disease with better accuracy:
neutralizing the international normalized ratio pitfalls. Hepatology 2007, 46:295-296.